A Study in Adults and Adolescents With Angelman Syndrome (STARS)
Public ClinicalTrials.gov record NCT02996305. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of Gaboxadol
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to assess the safety and tolerability of oral OV101 (gaboxadol) in adult and adolescent subjects with Angelman syndrome. In addition, several exploratory efficacy outcome measures will be investigated.
Study identification
- NCT ID
- NCT02996305
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 88 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 13 Years to 49 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2016 (Type not available)
- Primary completion
- Jun 7, 2018 (Actual)
- Completion
- Aug 6, 2018 (Actual)
- Last update posted
- Aug 3, 2025
2016 – 2018
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ovid Therapeutics Investigative Site | Phoenix | Arizona | — | — |
| Ovid Therapeutics Investigative Site | San Diego | California | — | — |
| Ovid Therapeutics Investigative Site | Gainesville | Florida | — | — |
| Ovid Therapeutics Investigative Site | Tampa | Florida | — | — |
| Ovid Therapeutics Investigative Site | Atlanta | Georgia | — | — |
| Ovid Therapeutics Investigative Site | Chicago | Illinois | — | — |
| Ovid Therapeutics Investigative Site | Boston | Massachusetts | — | — |
| Ovid Therapeutics Investigative Site | Lexington | Massachusetts | — | — |
| Ovid Therapeutics Investigative Site | Cincinnati | Ohio | — | — |
| Ovid Therapeutics Investigative Site | Media | Pennsylvania | — | — |
| Ovid Therapeutics Investigative Site | Greenwood | South Carolina | — | — |
| Ovid Therapeutics Investigative Site | Nashville | Tennessee | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02996305, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 3, 2025 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02996305 live on ClinicalTrials.gov.